Select the Right Data Collection Method for Real-World Evidence
Choosing the wrong RWE data source undermines your regulatory strategy. This framework helps pharma leaders select the right real-world data collection method based on your programme’s research question.
Cell Therapy for Solid Tumours: Current Challenges and New Advances
Cell therapy for solid tumours faces unique biological barriers. This analysis unpacks the engineering strategies pharma leaders must understand for R&D success in 2026.
Why Gynaecological Cancers Are Some of Pharma’s Most Important Challenges
Gynaecological cancers remain a major pharma challenge. Explore how disease burden, access, tumour biology, and precision medicine are shaping oncology R&D.
Design and Run Smarter Gynaecological Oncology Clinical Trials
Explore how adaptive design, biomarkers, AI, and smarter recruitment are shaping gynaecological cancer clinical trials and clinical development.
Camizestrant Approval: First ctDNA-Guided Cancer Care
The camizestrant FDA approval is the first for a ctDNA-guided cancer treatment. Find out why the FDA overruled its own advisers and what sponsors must plan next.
Can Deep Learning Survive the Precision Medicine Paradox?
As precision medicine narrows patient cohorts to rare‑disease scales, deep learning models face a paradox of data scarcity and overfitting that threatens the future of clinical AI.